Our Work
Latham Advises Crystalys Therapeutics on US$130 Million Series B Financing
July 22, 2026
Firm represents the clinical-stage biopharmaceutical company in financing to advance global phase 3 development and commercialization of dotinurad for gout.
Crystalys Therapeutics, Inc. (Crystalys), a clinical-stage biopharmaceutical company addressing the significant unmet medical needs of people living with gout, has announced the closing of an oversubscribed US$130 million Series B financing to support the late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once-daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout.
Latham & Watkins LLP advised Crystalys in the offering with a corporate team led by San Diego partners Cheston Larson and Christian Hollweg, with associates Alex Stuart-Lovell and Katie Raya.